Mutations in the E2-PePHD region of hepatitis C virus genotype-3a and correlation with response to interferon and ribavirin combination therapy in Pakistani patients

Virology Journal

Volumn 7, Issue , 2010, Pages

  Afzal, Samia ^a   Idrees, Muhammad ^a   Akram, Madiha ^a   Awan, Zunaira ^a   Khubaib, Bushra ^a   Aftab, Mahwish ^a   Fatima, Zareen ^a   Badar, Sadaf ^a   Hussain, Abrar ^a  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GLUTAMINE; LEUCINE; RIBAVIRIN; ANTIVIRUS AGENT; GLYCOPROTEIN E2, HEPATITIS C VIRUS; INITIATION FACTOR 2; INTERFERON; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MUTATIONAL ANALYSIS; PHOSPHORYLATION HOMOLOGY DOMAIN; PROTEIN DOMAIN; SEQUENCE ANALYSIS; TREATMENT RESPONSE; CHEMISTRY; DRUG COMBINATION; GENETICS; MUTATION; PAKISTAN; PROTEIN TERTIARY STRUCTURE; SEQUENCE ALIGNMENT; VIROLOGY;

EUKARYOTA; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 3;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EUKARYOTIC INITIATION FACTOR-2; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; MUTATION; PAKISTAN; PROTEIN STRUCTURE, TERTIARY; RIBAVIRIN; SEQUENCE ALIGNMENT; VIRAL ENVELOPE PROTEINS;

EID: 78650634419     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-377     Document Type: Article

References (18)

1. Epidemiology of hepatitis C virus infection. MJ Alter, World J Gastroenterol 2007 13 2436 2441 17552026
2. Global epidemiology of hepatitis C virus infection. CW Shepard L Finelli MJ Alter, Lancet Infect Dis 2005 5 558 567 10.1016/S1473-3099(05)70216-4 16122679
3. High prevalence of hepatitis C virus infection in the largest province of Pakistan. M Idrees A Lal M Naseem M Khalid, J Dig Dis 2008 9 95 103 10.1111/j.1751-2980.2008.00329.x 18419643
4. Molecular virology of hepatitis C virus (HCV) : 2006 update. V Brass D Moradpour HE Blum, Int J Med Sci 2006 3 29 34 16614739
5. The treatment of chronic viral hepatitis. JH Hoofnagle AM di Bisceglie, N Engl J Med 1997 336 5 347 356 10.1056/NEJM199701303360507 9011789
6. Future therapy of hepatitis C. JG McHutchison K Patel, Hepatology 2002 36 5 Suppl 1 245 252 10.1002/hep.1840360731 12407600
7. Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection. SJ Keam RS Cvetkovic, Drugs 2008 68 1273 1317 10.2165/00003495-200868090-00006 18547135
8. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Y Shiratori N Kato O Yokosuka F Imazeki E Hashimoto N Hayashi, Tokyo-Chiba Hepatitis Research Group 1997 113 558 66
9. The Double-stranded RNA-activated Protein Kinase PKR. Translational Control of Gene Expression. RJ Kaufman, Cold Spring Harbor Laboratory Press 2 2000 503 527
10. Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. H Le Guillou-Guillemette S Vallet C Gaudy-Graffin C Payan A Pivert A Goudeau F Lunel-Fabiani, World J Gastroenterol 2007 13 17 2416 2426 17552024
11. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response. C Sarrazin I Kornetzky B Ruster JH Lee B Kronenberger K Bruch WK Roth S Zeuzem, Hepatology 2000 31 6 1360 1370 10.1053/jhep.2000.7987 10827164 (Pubitemid 30351300)
12. Variations within hepatitis C virus E2 protein and response to interferon treatment. S Lo HH Lin, Virus Res 2001 75 2 107 112 10.1016/S0168-1702(01) 00224-6 11325465
13. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b. T Saito T Ito T tto H Ishiko M Yonaha K Morikawa A Miyokawa K Mitamura, Am J Gastroenterol 2003 98 6 1377 1383 10.1111/j.1572-0241.2003. 07469.x 12818284
14. Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment. T Berg Mas Marques M Hohne B Wiedenmann U Hopf E Schreier, Hepatology 2000 32 6 1386 1395 10.1053/jhep.2000.20527 11093746
15. Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy. K Chayama F Suzuki A Tsubota M Kobayashi Y Arase S Saitoh Y Suzuki N Murashima K Ikeda N Takahashi M Kinoshita H Kumada, Hepatology 2000 32 5 1138 1144 10.1053/jhep.2000.19364 11050067
16. Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon. M Gerotto F Dal Pero P Pontisso F Noventa A Gatta A Alberti, Gastroenterology 2000 119 6 1649 1655 10.1053/gast.2000.20230 11113086
17. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. CH Hung CM Lee SN Lu JF Lee JH Wang HD Tung TM Chen TH Hu WJ Chen CS Changchien, J Viral Hepat 2003 10 2 87 94 10.1046/j.1365-2893.2003.00414.x 12614464
18. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. D Taylor ST Shi PR Romano GN Barber MM Lai, Science 1999 285 5424 107 110 10.1126/science.285.5424.107 10390359